• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Roivant Sciences Ltd (NQ: ROIV )

    11.68 +0.13 (+1.13%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,778,948
    Open 11.56
    Bid (Size) 11.55 (10)
    Ask (Size) 11.99 (1)
    Prev. Close 11.55
    Today's Range 11.55 - 11.75
    52wk Range 8.465 - 13.05
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
    From Roivant Sciences
    Via GlobeNewswire
    Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. 
    From Roivant Sciences
    Via GlobeNewswire

    Performance

    YTD
    +2.91%
    +2.91%
    1 Month
    +4.19%
    +4.19%
    3 Month
    +13.40%
    +13.40%
    6 Month
    +0.69%
    +0.69%
    1 Year
    +25.86%
    +25.86%

    More News

    Read More
    Price Over Earnings Overview: Roivant Sciences
    Via Benzinga
    4 Analysts Assess Roivant Sciences: What You Need To Know
    Via Benzinga
    Evaluating Roivant Sciences: Insights From 6 Financial Analysts
    Via Benzinga
    The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
    Via Benzinga
    Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
    Via Benzinga
    Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
    Via Benzinga
    Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    From Roivant Sciences
    Via GlobeNewswire
    Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
    Via Benzinga
    Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
    From Roivant Sciences
    Via GlobeNewswire
    Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
    From Roivant Sciences
    Via GlobeNewswire
    What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
    Via Benzinga
    Roivant Provides Update on Graves’ Disease Development Program
    From Roivant Sciences
    Via GlobeNewswire
    Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
    Via Investor's Business Daily
    Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
    From Roivant Sciences
    Via GlobeNewswire
    ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024
    Via InvestorPlace
    Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
    Via Benzinga
    Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
    From Roivant Sciences
    Via GlobeNewswire
    Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
    Via InvestorPlace
    3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.